Universitat Ramon Llull. IQS
2025-06-13
A potent drug delivery system (DDS) based on poly(β-amino ester)s (pBAEs) to tackle multidrug resistance (MDR) in lung cancer by codelivering siRNA targeting antiapoptotic BCL-2 and doxorubicin (DOX) has been prepared. Engineered via strain-promoted azide–alkyne cycloaddition (SPAAC) to attach a tripeptide end-chain moiety and thiol–disulfide exchange to conjugate DOX, the system employs a hydrazone linker for dual pH- and redox-responsive release. This ensures precise tumor targeting with minimal leakage in the circulation. In multidrug-resistant lung cancer cells (GLC-4/ADR), it sharply downregulates BCL-2 expression, amplifying DOX’s therapeutic impact.
Article
Published version
English
Combination therapy; Drug delivery; Multidrug-resistance; siRNA; Poly(β-amino ester); Stimuli-responsive; Strain-promoted azide−alkyne cycloaddition (SPAAC); Thiol−disulfide exchange; Teràpia combinada; Administració de fàrmacs; Resistència a múltiples fàrmacs
p.12
American Chemical Society
ACS Applied Polymer Materials 2025, 7 (11), 7013–7024
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2019 FI_B01170
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2020 FI_B1 00112
info:eu-repo/grantAgreement/SUR del DEC i FSE/FI/2021 FI_B2 00165
info:eu-repo/grantAgreement/MCI/PN I+D/PID2021-126346OB-I00
info:eu-repo/grantAgreement/SUR del DEC/SGR/SGR 2021 00537
IQS [794]